InflaRx (IFRX) Capital Expenditures (2016 - 2026)
InflaRx (IFRX) posted Capital Expenditures of -$11083.4 for Q1 2026, down 104.15% sequentially from $266960.6 in Q4 2025, and down 0.87% YoY from -$11180.6 in Q1 2025.
InflaRx (IFRX) Capital Expenditures (2016 - 2026) Analysis & Trends
InflaRx has reported Capital Expenditures for 11 years, with the latest figure at -$11083.4 in Q1 2026.
- Quarterly Capital Expenditures fell 0.87% year-over-year to -$11083.4 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $135796.7 (up 141.98% YoY) and the FY2025 annual result came in at $130712.4, up 157.66% from the prior year.
- Capital Expenditures fell to -$11083.4 in Q1 2026 per IFRX's latest filing, from $266960.6 in the prior quarter.
- Over five years, Capital Expenditures peaked at $266960.6 in Q4 2025 and troughed at -$147408.4 in Q4 2022.
- A 5-year average of $5573.7 and a median of -$10988.0 in 2025 frame the typical range for Capital Expenditures.
- The widest YoY moves for Capital Expenditures: up 225.02% in 2025, down 5467.55% in 2025.
- Over 5 years, Capital Expenditures stood at -$147408.4 in 2022, then soared by 192.73% to $136689.6 in 2023, then sank by 39.91% to $82135.4 in 2024, then surged by 225.02% to $266960.6 in 2025, then plunged by 104.15% to -$11083.4 in 2026.
- According to Business Quant data, Capital Expenditures over the past three periods registered -$11083.4, $266960.6, and -$102844.1 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capex (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.89 Bn | 131.04 Bn | 2.84 Bn | 112.20 Mn |
| 2 | Regeneron Pharmaceuticals | 86.05 Bn | 78.06 Bn | 3.93 Bn | 240.20 Mn |
| 3 | Argenx Se | 65.56 Bn | 60.38 Bn | 1.37 Bn | - |
| 4 | Moderna | 55.46 Bn | 50.32 Bn | 52.00 Mn | 37.00 Mn |
| 5 | BeOne Medicines | 42.12 Bn | 37.02 Bn | 1.53 Bn | 25.02 Mn |
| 6 | Alnylam Pharmaceuticals | 31.62 Bn | 28.31 Bn | 992.69 Mn | 34.68 Mn |
| 7 | BioNTech SE | 27.70 Bn | 9.30 Bn | 668.28 Mn | -73.57 Mn |
| 8 | Insmed | 27.51 Bn | 26.35 Bn | 358.27 Mn | 6.26 Mn |
| 9 | Royalty Pharma | 27.38 Bn | 26.54 Bn | - | 251.02 Mn |
| 10 | InflaRx | 139.29 Mn | -44.96 Mn | 2.74 Bn | -42,370.41 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -11,083.45 |
| Mar 31, 2026 | -11,083.45 |
| Dec 31, 2025 | 266,960.58 |
| Dec 31, 2025 | 266,960.58 |
| Sep 30, 2025 | -102,844.11 |
| Sep 30, 2025 | -102,844.11 |
| Jun 30, 2025 | -17,236.35 |
| Jun 30, 2025 | -17,236.35 |
| Mar 31, 2025 | -10,987.98 |
| Mar 31, 2025 | -10,987.98 |
| Dec 31, 2024 | 82,135.45 |
| Dec 31, 2024 | 82,135.45 |
| Sep 30, 2024 | -1,847.21 |
| Sep 30, 2024 | -1,847.21 |
| Jun 30, 2024 | -13,182.18 |
| Jun 30, 2024 | -13,182.18 |
| Mar 31, 2024 | -17,456.75 |
| Mar 31, 2024 | -17,456.75 |
| Dec 31, 2023 | 136,689.56 |
| Dec 31, 2023 | 136,689.56 |